ArticleMedicine2025
Inflammatory bowel disease and hearing loss: A study of Mendelian randomization.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study explored the intriguing causal relationship between inflammatory bowel disease (IBD) and risk of hearing loss (HL). Here, we aimed to quantify the role of autoimmunity as a potential mediator. We pooled data from genome-wide association studies (GWAS) for ulcerative colitis (UC), Crohn disease (CD), and autoimmunity from the European IEU database and genome-wide association studies (GWAS) for HL from the Finnish database. We then applied a range of rigorous statistical methods, including inverse-variance weighted (IVW), Mendelian randomization Egger regression (MR-egger), weighted median (WME), simple mode (SM), and weighted mode (WM), to perform Mendelian randomization analysis and evaluate the causal relationship between IBD and HL risk using odds ratios (OR) and 95% confidence intervals (CI). We also conducted Cochran Q heterogeneity test using IVW and MR-Egger regression (MR-egger), and multiple validity tests using Mendelian randomization pleiotropy residual sum and outlier (MR-PRESSO), and sensitivity analysis using the MR_leaveoneout_plot function. F-values were computed to assess the presence of weak instrumental variable bias. IVW results showed that in the classification of IBD, not only CD was a risk factor for HL [OR: 1.045, 95%CI: 1.007-1.086, P = .019], but UC was also a risk factor for HL [OR:1.370, 95%CI: 1.027-1.828, P = .031]. CD was a risk factor for autoimmunity [OR: 1.005, 95%CI: 1.003-1.008, P < .001], UC was a risk factor for autoimmunity [OR: 1.092, 95%CI: 1.051-1.135, P < .001], and autoimmunity was also a risk factor for HL [OR: 2.898, 95%CI: 1.048-8.009, P = .040]. However, the relationship between CD and HL (P = .127) or between UC and HL (P = .083) was not mediated by autoimmunity. The risk of HL is directly increased by CD and UC. The role of autoimmunity in this process is not a mediating factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.